Portugal
Ipca Laboratories Ltd (BOM:524494) Q3 2024 Earnings Call Transcript Highlights: Strong Domestic Growth and Improved Margins Amid Export Challenges
Domestic Formulation Business Growth: 11% for the quarter.Chronic Market Growth: 15.9% for Ipca, compared to market growth of 11%.Acute Segment Growth: 11.3% f